Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study.

ICI-associated pituitary adverse events have significantly increased, and their clinical characteristics should be kept in mind by oncologists and endocrinologists who manage patients treated by immunotherapy.